The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Phase I/II ARROS-1 study of zidesamtinib in ROS1 fusion-positive solid tumors
Benjamin Besse, MD, PhD, Gustave Roussy, Villejuif, France, discusses the promising results of zidesamtinib, a novel TRK-sparing ROS1 tyrosine kinase inhibitor, in patients with heavily pretreated ROS1+ non-small cell lung cancer (NSCLC). In the Phase I ARROS-1 study (NCT05118789), zidesamtinib demonstrated a favorable safety profile and encouraging efficacy in patients with advanced ROS1+ NSCLC, even in those with multiple prior therapies and resistance mutations like G2032R. Importantly, zidesamtinib showed activity in patients with brain metastases, a significant challenge in ROS1+ NSCLC. These results suggest that zidesamtinib may be a valuable treatment option for patients with this difficult-to-treat disease. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
